Peer-influenced content. Sources you trust. No registration required. This is HCN.

Pharmacy TodayIncreasing Use of Prescription Digital Therapeutics

Because of their distinct modes of action, digital therapeutics (DTx) and PDTs are extending the range of available treatments beyond conventional pharmacology.

Pharmacists are increasingly being called upon to provide information and support to patients using prescription digital therapeutics (PDTs). These software applications are designed to deliver evidence-based treatments for medical conditions, and they have the potential to improve patient outcomes and reduce healthcare costs.

Key Points:
  • PDTs are FDA-approved software applications that are used to treat a variety of medical conditions, including chronic diseases, mental health disorders, and pain.
  • PDTs can be used to improve adherence to medication regimens and to provide behavioral interventions.
  • The market for PDTs is expected to grow rapidly in the coming years.
  • Pharmacists will need to be trained on how to use PDTs and how to integrate them into patient care.
  • They will also need to be able to educate patients about PDTs and their benefits.
Additional Points:
  • The FDA has approved several PDTs for the treatment of a variety of conditions, including smoking cessation, chronic pain, and obesity.
  • A recent study found that PDTs can reduce healthcare costs by up to $3,000 per patient per year.
  • Pharmacists are well-positioned to play a key role in the adoption and use of PDTs, as they have a strong understanding of medication adherence and patient education.

More on Digital Therapeutics

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form